These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 28800475)

  • 1. Biological, immunological and functional properties of two novel multi-variant chimeric recombinant proteins of CSP antigens for vaccine development against Plasmodium vivax infection.
    Shabani SH; Zakeri S; Salmanian AH; Amani J; Mehrizi AA; Snounou G; Nosten F; Andolina C; Mourtazavi Y; Djadid ND
    Mol Immunol; 2017 Oct; 90():158-171. PubMed ID: 28800475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel chimeric Plasmodium vivax circumsporozoite protein induces biologically functional antibodies that recognize both VK210 and VK247 sporozoites.
    Yadava A; Sattabongkot J; Washington MA; Ware LA; Majam V; Zheng H; Kumar S; Ockenhouse CF
    Infect Immun; 2007 Mar; 75(3):1177-85. PubMed ID: 17158893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prime-boost vaccination with recombinant protein and adenovirus-vector expressing Plasmodium vivax circumsporozoite protein (CSP) partially protects mice against Pb/Pv sporozoite challenge.
    de Camargo TM; de Freitas EO; Gimenez AM; Lima LC; de Almeida Caramico K; Françoso KS; Bruna-Romero O; Andolina C; Nosten F; Rénia L; Ertl HCJ; Nussenzweig RS; Nussenzweig V; Rodrigues MM; Reyes-Sandoval A; Soares IS
    Sci Rep; 2018 Jan; 8(1):1118. PubMed ID: 29348479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of Multifunctional Broadly Reactive T Cell Responses by a Plasmodium vivax Circumsporozoite Protein Recombinant Chimera.
    Cabrera-Mora M; Fonseca JA; Singh B; Oliveira-Ferreira J; Lima-Junior Jda C; Calvo-Calle JM; Moreno A
    Infect Immun; 2015 Sep; 83(9):3749-61. PubMed ID: 26169267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity of a prime-boost vaccine containing the circumsporozoite proteins of Plasmodium vivax in rodents.
    Teixeira LH; Tararam CA; Lasaro MO; Camacho AG; Ersching J; Leal MT; Herrera S; Bruna-Romero O; Soares IS; Nussenzweig RS; Ertl HC; Nussenzweig V; Rodrigues MM
    Infect Immun; 2014 Feb; 82(2):793-807. PubMed ID: 24478093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serological responses to a soluble recombinant chimeric Plasmodium vivax circumsporozoite protein in VK210 and VK247 population.
    Cheng Y; Ito D; Sattabongkot J; Lim CS; Kong DH; Ha KS; Wang B; Tsuboi T; Han ET
    Malar J; 2013 Sep; 12():323. PubMed ID: 24034268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 1/2a Trial of Plasmodium vivax Malaria Vaccine Candidate VMP001/AS01B in Malaria-Naive Adults: Safety, Immunogenicity, and Efficacy.
    Bennett JW; Yadava A; Tosh D; Sattabongkot J; Komisar J; Ware LA; McCarthy WF; Cowden JJ; Regules J; Spring MD; Paolino K; Hartzell JD; Cummings JF; Richie TL; Lumsden J; Kamau E; Murphy J; Lee C; Parekh F; Birkett A; Cohen J; Ballou WR; Polhemus ME; Vanloubbeeck YF; Vekemans J; Ockenhouse CF
    PLoS Negl Trop Dis; 2016 Feb; 10(2):e0004423. PubMed ID: 26919472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A universal vaccine candidate against Plasmodium vivax malaria confers protective immunity against the three PvCSP alleles.
    Gimenez AM; Salman AM; Marques RF; López-Camacho C; Harrison K; Kim YC; Janse CJ; Soares IS; Reyes-Sandoval A
    Sci Rep; 2021 Sep; 11(1):17928. PubMed ID: 34504134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trials for the co-expression of the merozoite surface protein-1 and circumsporozoite protein genes of Plasmodium vivax.
    Lee C; Chung KW; Kim TS; Choi KM; Choi YK; Chung NJ; Rhie HG; Lee HS; Lee SJ; Lee HW
    Exp Parasitol; 2011 Nov; 129(3):227-33. PubMed ID: 21907198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a Plasmodium berghei transgenic parasite expressing the full-length Plasmodium vivax circumsporozoite VK247 protein for testing vaccine efficacy in a murine model.
    Mizutani M; Fukumoto S; Soubeiga AP; Soga A; Iyori M; Yoshida S
    Malar J; 2016 Apr; 15(1):251. PubMed ID: 27129682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serological responses to a soluble recombinant circumsporozoite protein-VK210 of Plasmodium vivax (rPvCSP-VK210) among Iranian malaria patients.
    Nateghpour M; Etemadi S; Motevalli Haghi A; Eslami H; Mohebali M; Farivar L
    Eur J Med Res; 2021 Nov; 26(1):134. PubMed ID: 34823591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation, characterization and immunogenicity of a novel chimeric recombinant protein based on Plasmodium vivax AMA-1 and MSP1
    Rocha MV; Françoso KS; Lima LC; Camargo TM; Machado RLD; Costa FTM; Rénia L; Nosten F; Russell B; Rodrigues MM; Soares IS
    Vaccine; 2017 Apr; 35(18):2463-2472. PubMed ID: 28341111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunological evaluation of two novel engineered Plasmodium vivax circumsporozoite proteins formulated with different human-compatible vaccine adjuvants in C57BL/6 mice.
    Shabani SH; Zakeri S; Mortazavi Y; Mehrizi AA
    Med Microbiol Immunol; 2019 Dec; 208(6):731-745. PubMed ID: 31025102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity of recombinant proteins consisting of Plasmodium vivax circumsporozoite protein allelic variant-derived epitopes fused with Salmonella enterica Serovar Typhimurium flagellin.
    Leal MT; Camacho AG; Teixeira LH; Bargieri DY; Soares IS; Tararam CA; Rodrigues MM
    Clin Vaccine Immunol; 2013 Sep; 20(9):1418-25. PubMed ID: 23863502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-allele specific antibody responses to genetically distinct variant forms of Plasmodium vivax Duffy binding protein (PvDBP-II) in Iranians exposed to seasonal malaria transmission.
    Valizadeh V; Zakeri S; Mehrizi AA; Djadid ND
    Acta Trop; 2014 Aug; 136():89-100. PubMed ID: 24704284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antigenicity and immunogenicity of a novel Plasmodium vivax circumsporozoite derived synthetic vaccine construct.
    Céspedes N; Jiménez E; Lopez-Perez M; Rubiano K; Felger I; Alonso P; Arévalo-Herrera M; Corradin G; Herrera S
    Vaccine; 2014 May; 32(26):3179-86. PubMed ID: 24731811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity of PvCyRPA, PvCelTOS and Pvs25 chimeric recombinant protein of
    Matos ADS; Soares IF; Rodrigues-da-Silva RN; Rodolphi CM; Albrecht L; Donassolo RA; Lopez-Camacho C; Ano Bom APD; Neves PCDC; Conte FP; Pratt-Riccio LR; Daniel-Ribeiro CT; Totino PRR; Lima-Junior JDC
    Front Immunol; 2024; 15():1392043. PubMed ID: 38962015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Broadly neutralizing epitopes in the Plasmodium vivax vaccine candidate Duffy Binding Protein.
    Chen E; Salinas ND; Huang Y; Ntumngia F; Plasencia MD; Gross ML; Adams JH; Tolia NH
    Proc Natl Acad Sci U S A; 2016 May; 113(22):6277-82. PubMed ID: 27194724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of the Plasmodium vivax merozoite surface protein 1 paralog in the induction of naturally acquired antibody and memory B cell responses.
    Min HMK; Changrob S; Soe PT; Han JH; Muh F; Lee SK; Chootong P; Han ET
    Malar J; 2017 Aug; 16(1):354. PubMed ID: 28854974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of Plasmodium falciparum and Plasmodium vivax circumsporozoite protein repeat multiple antigen constructs (MAC).
    Udhayakumar V; Saekhou A; Fang S; Jue D; Wohlhueter RM; Lal AA
    Vaccine; 1998; 16(9-10):982-8. PubMed ID: 9682348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.